Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Empaveli
Pharma
Apellis snatches broad kidney disease expansion for Empaveli
Apellis's Empaveli is the first drug to reach the IC-MPGN market and will compete against Novartis' Fabhalta in C3G, another rare kidney disease.
Zoey Becker
Jul 28, 2025 8:00pm
Sobi places $300M bet on Empaveli in partnership with Apellis
Jul 1, 2025 11:28am
Apellis' Syfovre faces tough road ahead in GA market: analyst
May 14, 2025 11:10am
Novartis' Fabhalta nod in C3G leaves room for rival Apellis
Mar 21, 2025 10:37am
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Nov 5, 2024 3:41pm
Novartis, Apellis roll out rival datasets in rare kidney disease
Oct 28, 2024 10:03am
